Mount Yale Investment Advisors LLC Reduces Position in AstraZeneca PLC (NASDAQ:AZN)

Mount Yale Investment Advisors LLC reduced its holdings in AstraZeneca PLC (NASDAQ:AZN) by 6.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 44,653 shares of the company’s stock after selling 3,162 shares during the period. Mount Yale Investment Advisors LLC’s holdings in AstraZeneca were worth $2,926,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Blue Trust Inc. boosted its stake in AstraZeneca by 38.4% during the fourth quarter. Blue Trust Inc. now owns 27,712 shares of the company’s stock worth $1,816,000 after buying an additional 7,686 shares during the last quarter. Jamison Private Wealth Management Inc. boosted its position in shares of AstraZeneca by 4.2% during the 4th quarter. Jamison Private Wealth Management Inc. now owns 28,334 shares of the company’s stock valued at $1,856,000 after acquiring an additional 1,141 shares during the last quarter. Asio Capital LLC increased its position in AstraZeneca by 11.6% during the fourth quarter. Asio Capital LLC now owns 53,541 shares of the company’s stock worth $3,508,000 after purchasing an additional 5,569 shares during the last quarter. Grimes & Company Inc. raised its stake in AstraZeneca by 5.8% during the fourth quarter. Grimes & Company Inc. now owns 5,393 shares of the company’s stock worth $353,000 after purchasing an additional 297 shares during the period. Finally, Goelzer Investment Management Inc. boosted its holdings in AstraZeneca by 37.9% in the 4th quarter. Goelzer Investment Management Inc. now owns 83,689 shares of the company’s stock valued at $5,483,000 after purchasing an additional 22,983 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Up 0.7 %

AZN opened at $69.06 on Monday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $66.44 and a 200-day simple moving average of $74.14. The firm has a market cap of $214.16 billion, a P/E ratio of 33.04, a P/E/G ratio of 1.13 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. AstraZeneca’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the business posted $0.87 EPS. On average, equities analysts expect that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.